[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609824":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":34,"centralContacts":43,"locations":49,"responsibleParty":241,"collaborators":34,"id":243,"slug":34,"hasResults":244,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":244,"sex":250,"minAge":251,"maxAge":34,"enrollmentInfo":252,"targetDuration":34,"studyType":255,"phases":256,"briefSummary":258,"conditions":259,"keywords":34,"overallStatus":52,"whyStopped":34,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},{"fullName":5,"class":6},"NewAmsterdam Pharma","INDUSTRY",[8,14,19,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Obicetrapib\u002FEzetimibe","EXPERIMENTAL","obicetrapib 10 mg + ezetimibe 10 mg FDC daily",[13],"Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily",{"label":15,"type":10,"description":16,"interventionNames":17},"Obicetrapib","obicetrapib 10 mg daily",[18],"Drug: Obicetrapib 10 mg",{"label":20,"type":21,"description":22,"interventionNames":23},"Placebo","PLACEBO_COMPARATOR","Placebo on top of guideline-recommended lipid-lowering therapy",[24],"Other: Placebo",{"label":26,"type":10,"description":27,"interventionNames":28},"Open-Label Extension","Open-Label Extension (OLE) with the FDC of Obicetrapib 10 mg and Ezetimibe 10 mg",[13],[30,35,39],{"type":31,"name":11,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","FDC",[9,26],null,{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Obicetrapib 10 mg","monotherapy",[15],{"type":40,"name":20,"description":41,"armGroupLabels":42,"otherNames":34},"OTHER","placebo on top of guideline-recommended lipid modifying therapy",[20],[44],{"name":45,"role":46,"phone":47,"phoneExt":34,"email":48},"Gagandeep Dhillon","CONTACT","519-209-2341","Gagandeep.dhillon@fortrea.com",[50,63,73,83,89,97,106,116,126,136,146,156,166,176,184,193,203,213,222,232],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":34},"Clinical Research Institute of Arizona","RECRUITING","Sun City West","Arizona","85375","United States",{"type":58,"coordinates":59},"Point",[60,61],-112.34127,33.66198,{"lat":61,"lon":60},{"facility":64,"status":52,"city":65,"state":66,"zip":67,"country":56,"cosmosGeoPoint":68,"geoPoint":72,"contacts":34},"Scripps Health - Whittier Diabetes Institute","La Jolla","California","92037",{"type":58,"coordinates":69},[70,71],-117.2742,32.84727,{"lat":71,"lon":70},{"facility":74,"status":52,"city":75,"state":76,"zip":77,"country":56,"cosmosGeoPoint":78,"geoPoint":82,"contacts":34},"UF Health Jackson","Jacksonville","Florida","32209",{"type":58,"coordinates":79},[80,81],-81.65565,30.33218,{"lat":81,"lon":80},{"facility":84,"status":52,"city":75,"state":76,"zip":85,"country":56,"cosmosGeoPoint":86,"geoPoint":88,"contacts":34},"East Coast Institute of Research LLC","32216",{"type":58,"coordinates":87},[80,81],{"lat":81,"lon":80},{"facility":84,"status":52,"city":90,"state":76,"zip":91,"country":56,"cosmosGeoPoint":92,"geoPoint":96,"contacts":34},"Lake City","32055",{"type":58,"coordinates":93},[94,95],-82.63929,30.18968,{"lat":95,"lon":94},{"facility":98,"status":52,"city":99,"state":76,"zip":100,"country":56,"cosmosGeoPoint":101,"geoPoint":105,"contacts":34},"Floridian Clinical Research","Miami Lakes","33016",{"type":58,"coordinates":102},[103,104],-80.30866,25.90871,{"lat":104,"lon":103},{"facility":107,"status":52,"city":108,"state":109,"zip":110,"country":56,"cosmosGeoPoint":111,"geoPoint":115,"contacts":34},"Louisville Metabolic and Atherosclerosis Research Center (L-MARC)","Louisville","Kentucky","40213",{"type":58,"coordinates":112},[113,114],-85.75941,38.25424,{"lat":114,"lon":113},{"facility":117,"status":52,"city":118,"state":119,"zip":120,"country":56,"cosmosGeoPoint":121,"geoPoint":125,"contacts":34},"MD Medical Research","Oxon Hill","Maryland","20745",{"type":58,"coordinates":122},[123,124],-76.9897,38.80345,{"lat":124,"lon":123},{"facility":127,"status":52,"city":128,"state":129,"zip":130,"country":56,"cosmosGeoPoint":131,"geoPoint":135,"contacts":34},"Jefferson City Medical Group","Jefferson City","Missouri","65109",{"type":58,"coordinates":132},[133,134],-92.17352,38.5767,{"lat":134,"lon":133},{"facility":137,"status":52,"city":138,"state":139,"zip":140,"country":56,"cosmosGeoPoint":141,"geoPoint":145,"contacts":34},"Montana Medical Research","Missoula","Montana","59808",{"type":58,"coordinates":142},[143,144],-113.994,46.87215,{"lat":144,"lon":143},{"facility":147,"status":52,"city":148,"state":149,"zip":150,"country":56,"cosmosGeoPoint":151,"geoPoint":155,"contacts":34},"Inspira Health - Internal Medicine Associates","Bridgeton","New Jersey","08302",{"type":58,"coordinates":152},[153,154],-75.23408,39.42734,{"lat":154,"lon":153},{"facility":157,"status":52,"city":158,"state":159,"zip":160,"country":56,"cosmosGeoPoint":161,"geoPoint":165,"contacts":34},"Central New York Clinical Research","Manlius","New York","13104",{"type":58,"coordinates":162},[163,164],-75.97686,43.00201,{"lat":164,"lon":163},{"facility":167,"status":52,"city":168,"state":169,"zip":170,"country":56,"cosmosGeoPoint":171,"geoPoint":175,"contacts":34},"Velocity Clinical Research","Durham","North Carolina","27710",{"type":58,"coordinates":172},[173,174],-78.89862,35.99403,{"lat":174,"lon":173},{"facility":98,"status":52,"city":177,"state":169,"zip":178,"country":56,"cosmosGeoPoint":179,"geoPoint":183,"contacts":34},"Greensboro","27408",{"type":58,"coordinates":180},[181,182],-79.79198,36.07264,{"lat":182,"lon":181},{"facility":185,"status":52,"city":186,"state":169,"zip":187,"country":56,"cosmosGeoPoint":188,"geoPoint":192,"contacts":34},"Centricity Research dba Lucas Research","Morehead City","28557",{"type":58,"coordinates":189},[190,191],-76.72604,34.72294,{"lat":191,"lon":190},{"facility":194,"status":52,"city":195,"state":196,"zip":197,"country":56,"cosmosGeoPoint":198,"geoPoint":202,"contacts":34},"Summit Research Group","Munroe Falls","Ohio","44262",{"type":58,"coordinates":199},[200,201],-81.43983,41.1445,{"lat":201,"lon":200},{"facility":204,"status":52,"city":205,"state":206,"zip":207,"country":56,"cosmosGeoPoint":208,"geoPoint":212,"contacts":34},"Juno Research LLC - Medical Center","Houston","Texas","77054",{"type":58,"coordinates":209},[210,211],-95.36327,29.76328,{"lat":211,"lon":210},{"facility":214,"status":52,"city":215,"state":206,"zip":216,"country":56,"cosmosGeoPoint":217,"geoPoint":221,"contacts":34},"Clinical Trials of Texas dba Flourish Research","San Antonio","78229",{"type":58,"coordinates":218},[219,220],-98.49363,29.42412,{"lat":220,"lon":219},{"facility":223,"status":52,"city":224,"state":225,"zip":226,"country":56,"cosmosGeoPoint":227,"geoPoint":231,"contacts":34},"Burke Internal Medicine","Burke","Virginia","22015-2234",{"type":58,"coordinates":228},[229,230],-77.27165,38.79345,{"lat":230,"lon":229},{"facility":233,"status":52,"city":234,"state":225,"zip":235,"country":56,"cosmosGeoPoint":236,"geoPoint":240,"contacts":34},"Burke International Medicine DBA Manassas Clinical Research Center","Manassas","20110",{"type":58,"coordinates":237},[238,239],-77.47527,38.75095,{"lat":239,"lon":238},{"type":242,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100609824",false,"NCT07219602","A Study to Evaluate the Effect of Obicetrapib\u002FEzetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome","A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome (RUBENS Trial)","RUBENS","Inclusion Criteria:\n\n* fasting serum LDL-C ≥ 70 mg\u002FdL (≥1.81 mmol\u002FL)\n* Have fasting TG ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL)\n* Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg\u002FdL (≥1.7mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL) and at least 2 risk factors\n* Are on stable guideline-recommended lipid-lowering therapy\n* Estimated glomerular filtration rate ≥15 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \\\u003C30%\n* Have been hospitalized for heart failure within 5 years prior to Screening\n* Have uncontrolled severe hypertension\n* Have a formal diagnosis of homozygous familial hypercholesterolemia\n* HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg\u002FdL (≥15.0 mmol\u002FL) at Screening\n* active liver disease","ALL","18 Years",{"count":253,"type":254},300,"ESTIMATED","INTERVENTIONAL",[257],"PHASE3","This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and\u002For Type 2 Diabetes Mellitus.",[260,261,262],"Lipidemia","Type 2 Diabetes (T2DM)","Metabolic Syndrome (MetS)","2026-03-06",{"date":265,"type":266},"2026-03-10","ACTUAL",{"date":268,"type":266},"2025-12-11",{"date":270,"type":254},"2028-06",{"name":5,"class":6},20]